Lauer tapped as new Raybow USA president

Lauer tapped as new Raybow USA president Image

Pete Newsome displays his “25 years of service” recognition with President Matt Lauer standing by.

Raybow USA, Inc. announced today that Peter Newsome, Ph.D., is stepping down as company president. Newsome will remain engaged as a company advisor, providing continued guidance to projects and counsel to executive management. Effective today, Matt Lauer, Ph.D., has been promoted from vice-president to president of Raybow USA.

“I am confident that Raybow has chosen my successor wisely by tapping Matt. As a long-time employee, Matt has steadily risen through both lab and management positions, not only picking up the necessary skills but also becoming an integral part of project and company history,” commented Newsome.

Lauer joined the company in 2016 as a synthetic chemist. He holds a Ph.D. from The Ohio State University and a Bachelor of Science in Chemistry from Northern Kentucky University. His extensive experience includes organic synthesis, catalysis, process development, and project management.

“Taking over as head of laboratory and business operations will be an exciting challenge, but we have a great team with impressive depth. I’m confident that Raybow USA is poised to build on the successes that both Pete and Roger kicked off more than 25 years ago,” Lauer said.

About Raybow USA, Inc.

Founded in 1998 as PharmAgra Labs by Peter Newsome and Roger Frisbee, the Brevard North Carolina company became part of Raybow in 2019. The facility is dedicated to early-stage drug development, encompassing cutting-edge R&D, preparation of clinical trial material and specialized small-scale manufacturing.

The site boasts a fully compliant cGMP laboratory and multi-Kg scale cGMP commercial manufacturing facility. Expansion projects are underway, ensuring the site’s continued ability to stay ahead of client needs and expectations.

About Raybow

Raybow is a global CDMO (Contract Development and Manufacturing Organization) focused on the development and manufacturing of small molecule APIs (active pharmaceutical ingredients) and finished dose drug products with facilities and employees in North America, Europe, and China.

Globally, Raybow is driven by a passion for solving complex chemical development and manufacturing challenges. In the relentless pursuit of excellence, Raybow embraces sustainable practices in process development and pharmaceutical production. Facilities pass rigorous inspections and regular audits by numerous international regulatory bodies, including the FDA (USA), PMDA (Japan), AIFA (Italy), and NMPA (China FDA), reaffirming a commitment to maintaining the highest standards of quality and safety.

Partnering with Raybow means choosing a leader in green process development, bringing a blend of innovation, quality, and environmental responsibility to every project. Raybow focuses on collaborations that help shape a healthier future.


Other Raybow News & Papers

Lauer tapped as new Raybow USA president

Lauer tapped as new Raybow USA president

Raybow to attend CPhI Barcelona

Join us October 24th thru the 26th in Barcelona.

Raybow to Attend Biotech Outsourcing Strategies Basel 2023

Join us July 4th and 5th in Basel

Raybow to Specialty & Agro Chemicals America Show in Savannah

Join us in Savannah for this annual showcase